207 results
8-K
EX-2.1
NBSE
NeuBase Therapeutics Inc
7 Mar 24
Other Events
4:01pm
claims against the Company, including, without limitation, tax obligations, all expenses related to the sale of the Company’s property and assets, all
8-K
EX-4.1
NBSE
NeuBase Therapeutics Inc
18 Oct 23
Entry into a Material Definitive Agreement
8:00am
without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all … and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall
8-K
EX-10.1
fgso sou7
30 Jun 23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
4:21pm
8-K
EX-10.3
n3zna4 7anfuhdy
30 Jun 23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
4:21pm
8-K
EX-4.1
pzwxcy 4hf
30 Jun 23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
4:21pm
8-K
EX-4.3
e2w9b4o7l t7s
30 Jun 23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
4:21pm
8-K
EX-4.2
dl6l gaex9hjelff
30 Jun 23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
4:21pm
8-K
EX-4.5
3x8 1tmssf5387
30 Jun 23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
4:21pm
8-K
EX-4.4
9o2rj5f6f jdsdzy1f4l
30 Jun 23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
4:21pm
8-K
EX-10.2
fwzudc8
30 Jun 23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
4:21pm
424B5
f58vay
30 Jun 23
Prospectus supplement for primary offering
8:42am
10-QT
0qvkn4f5fxo1xvxm
5 Jun 23
Quarterly report for transitional period
4:05pm
424B5
u99tt
29 Dec 22
Prospectus supplement for primary offering
5:03pm